Thaçi D, Körber A, von Kiedrowski R, et al. - Researchers conducted this PROSPECT study, an ongoing 24-week, single-cohort, non-interventional study, to evaluate former and concomitant psoriasis treatments and transition periods in moderate-to-severe psoriasis patients (n = 1,988; mean age was 48.1 ± 13.7 years) who were receiving secukinumab. The sample consisted of patients with moderate-to-severe psoriasis with a decision to receive secukinumab 300 mg. Data reported that 1,808 (90.9%) of patients had prior systemic treatment. In 44.3% of patients, concomitant treatment was reported. The median duration of the transition period from previous topical, conventional systemic and biologic treatments was 14.0, 30.0 and 44.5 days, respectively. At Week 24, PASI75/90/100 was attained by 86.1%, 68.5% and 39.7% of patients who began secukinumab treatment at baseline. Therefore, the PROSPECT gives a large prospective real-world analysis of secukinumab treatment and involves former and concomitant use of psoriasis treatments in individuals receiving secukinumab in a real-world setting. Effectiveness and safety of secukinumab were comparable to that seen in the clinical trial program for secukinumab in phase 2/3. No unexpected safety signals were noted.